Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS)

C. Moura; S. Bernatsky; M. Abrahamowicz; A. Papaioannou; L. Bessette; J. Adachi; D. Goltzman; J. Prior; N. Kreiger; T. Towheed; W. D. Leslie; S. Kaiser; G. Ioannidis; L. Pickard; L. A. Fraser; E. Rahme

doi:10.1007/s00198-014-2649-x

Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS)

C. Moura, S. Bernatsky, M. Abrahamowicz, A. Papaioannou, L. Bessette, J. Adachi, D. Goltzman, J. Prior, N. Kreiger, T. Towheed, W. D. Leslie, S. Kaiser, G. Ioannidis, L. Pickard, L. A. Fraser, E. Rahme

Immunology and Microbiology

科研成果: 期刊稿件 › 文章 › 同行评审

80 引用（Scopus）

源语言	英语
页（从-至）	1473-1481
页数	9
期刊	Osteoporosis International
卷	25
期	5
DOI	https://doi.org/10.1007/s00198-014-2649-x
出版状态	已出版 - 5月 2014

!!!ASJC Scopus Subject Areas

内分泌学、糖尿病和代谢

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s00198-014-2649-x

其它文件与链接

引用此

Moura, C., Bernatsky, S., Abrahamowicz, M., Papaioannou, A., Bessette, L., Adachi, J., Goltzman, D., Prior, J., Kreiger, N., Towheed, T., Leslie, W. D., Kaiser, S., Ioannidis, G., Pickard, L., Fraser, L. A., & Rahme, E. (2014). Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporosis International, 25(5), 1473-1481. https://doi.org/10.1007/s00198-014-2649-x

Moura, C, Bernatsky, S, Abrahamowicz, M, Papaioannou, A, Bessette, L, Adachi, J, Goltzman, D, Prior, J, Kreiger, N, Towheed, T, Leslie, WD, Kaiser, S, Ioannidis, G, Pickard, L, Fraser, LA & Rahme, E 2014, 'Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS)', Osteoporosis International, 卷 25, 号码 5, 页码 1473-1481. https://doi.org/10.1007/s00198-014-2649-x

@article{b03513baa1bf43389cd39eb9f640686f,

title = "Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS)",

keywords = "Fragility fractures, Osteoporosis, Selective serotonin reuptake inhibitor, Serotonin and noradrenaline reuptake inhibitors",

author = "C. Moura and S. Bernatsky and M. Abrahamowicz and A. Papaioannou and L. Bessette and J. Adachi and D. Goltzman and J. Prior and N. Kreiger and T. Towheed and Leslie, {W. D.} and S. Kaiser and G. Ioannidis and L. Pickard and Fraser, {L. A.} and E. Rahme",

note = "Funding Information: Lisa-Ann Fraser has been on the speaker{\textquoteright}s bureau for Amgen. Jonathan D. Adachi has been a consultant/speaker for Amgen, Eli Lilly, Merck, Novartis, and Warner Chilcot, and has conducted clinical trials for Amgen, Eli Lilly, Merck, and Novartis. David Goltzman has been an advisory board member or consultant for Amgen, Eli Lilly, Merck Frosst, and Novartis. William Leslie has received speaker fees from Amgen, Eli Lilly, and Novartis and research grants from Amgen and Genzyme.",

year = "2014",

month = may,

doi = "10.1007/s00198-014-2649-x",

language = "English",

volume = "25",

pages = "1473--1481",

journal = "Osteoporosis International",

issn = "0937-941X",

publisher = "Springer London",

number = "5",

}

TY - JOUR

T1 - Antidepressant use and 10-year incident fracture risk

T2 - The population-based Canadian Multicentre Osteoporosis Study (CaMoS)

AU - Moura, C.

AU - Bernatsky, S.

AU - Abrahamowicz, M.

AU - Papaioannou, A.

AU - Bessette, L.

AU - Adachi, J.

AU - Goltzman, D.

AU - Prior, J.

AU - Kreiger, N.

AU - Towheed, T.

AU - Leslie, W. D.

AU - Kaiser, S.

AU - Ioannidis, G.

AU - Pickard, L.

AU - Fraser, L. A.

AU - Rahme, E.

N1 - Funding Information: Lisa-Ann Fraser has been on the speaker’s bureau for Amgen. Jonathan D. Adachi has been a consultant/speaker for Amgen, Eli Lilly, Merck, Novartis, and Warner Chilcot, and has conducted clinical trials for Amgen, Eli Lilly, Merck, and Novartis. David Goltzman has been an advisory board member or consultant for Amgen, Eli Lilly, Merck Frosst, and Novartis. William Leslie has received speaker fees from Amgen, Eli Lilly, and Novartis and research grants from Amgen and Genzyme.

PY - 2014/5

Y1 - 2014/5

KW - Fragility fractures

KW - Osteoporosis

KW - Selective serotonin reuptake inhibitor

KW - Serotonin and noradrenaline reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84899623179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899623179&partnerID=8YFLogxK

U2 - 10.1007/s00198-014-2649-x

DO - 10.1007/s00198-014-2649-x

M3 - Article

C2 - 24566587

AN - SCOPUS:84899623179

SN - 0937-941X

VL - 25

SP - 1473

EP - 1481

JO - Osteoporosis International

JF - Osteoporosis International

IS - 5

ER -

Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS)

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此